This email address is being protected from spambots. You need JavaScript enabled to view it.

Our Goal

is to provide the most effective, innovative, and functional products for the compounding industry. In that spirit, we have committed significant resources to the study and validation of our technology.

We accomplish this by applying basic science to our research, with the goals of improving therapeutic options and advancing the profession through the publication of scholarly articles. Behind every study and product, there is a team of PhD-level scientists, chemists, and pharmacists dedicated in their pursuit of unsurpassed product innovation.

Optimized in Google Chrome or Mozilla Firefox. If you have issues accessing information on the website, please contact: This email address is being protected from spambots. You need JavaScript enabled to view it.


April 11, 2018

  • Testosterone Replacement Therapy in Hypogonadism

    A male patient in his seventies with symptoms of testosterone deficiency, such as loss of libido and a positive ADAM score, was dispensed testosterone 5% topical gel (Atrevis™ Hydrogel) for 6 months. The patient was very satisfied with PCCA formula 12674 and reported a negative ADAM score and a total testosterone laboratory result of 1,076 ƞg/dL post-treatment. - View

  • Evaluation of the in vitro Human Skin Percutaneous Absorption of Ketoprofen using the Franz Finite Dose IVPT Model

    The skin percutaneous absorption of ketoprofen incorporated in Anhydrous Lipoderm® (PCCA formula 12940) was evaluated using the Franz Finite Dose IVPT model and it was concluded that ketoprofen penetrates through and into human cadaver skin in vitro. - View

March 15, 2018

  • Second-degree Skin Burn Injury Following a Domestic Incident

    Burns caused by heat in domestic kitchens have a high incidence worldwide and commonly result in open wounds and skin scarring. This case study demonstrates the successful treatment of a second-degree skin burn with PCCA formulas 12781 (naltrexone 0.5% and aloe vera 0.2% in Spira -Wash) and 12830 (pentoxyfilline 1% in PracaSil-Plus). - View

  • Effects of Compounded Stanford Modified Oral Rinse (MucoLox) on the Survival and Migration of Oral Keratinocytes and Fibroblasts: Implications for Wound Healing

    In this study, we modified the Stanford oral rinse by including a proprietary mucoadhesive polymer called MucoLox, which we hypothesized would improve active pharmaceutical ingredient mucoadhesion. Characterization of this newly compounded oral rinse showed absence of cytotoxicity in human oral keratinocyte and fibroblast cell lines. - View

  • The Role of Transdermal Compounding in Opioid Safety

    Traditionally, opioid analgesics were reserved for a few select conditions, such as terminal illness and surgery, but currently opioids have been readily prescribed for multiple conditions. The objective of this manuscript is to clarify the current state of opioid use and to discuss alternative transdermal analgesic therapies in pain management. - View

denotes an impact-factor scientific journal.
denotes a publication authored by PCCA.

Sort by Category: 

Choose a Product:  







Anhydrous Lipoderm









denotes an impact-factor scientific journal.
denotes a publication authored by PCCA.


Jump to organization:  


European Paediatric Formulation Initiative

PCCA is the exclusive sponsor of the best poster and oral presentations at the EuPFI annual scientific conference

9th EuPFI Conference: Warsaw (Poland) 20th-21st September, 2017

  • Enhanced oromucosal permeation of midazolam hydrochloride released from mucoadhesive buccal films using methylated β-cyclodextrins

  • Dissolution and compatibility of hydrocortisone granules following exposure to common paediatric administration fluids and food matrices

  • Manipulation of hydrocortisone tablets: Do parents follow the advice from healthcare practitioners?

  • Best Oral Presentation: Extrusion of highly drug-loaded wax-extrudates for paediatric use

8th EuPFI Conference: Lisbon (Portugal) 21st-22nd September, 2016

  • A Novel Approach to Assess and Improve Palatability of an Inhaled Asset Using the Rat Brief Access Taste Aversion Assay and an In Silico Model of Salivary Flow

  • Simulating Different Dosing Scenarios for a Paediatric Valproic Acid ER Formulation in a New Paediatric Multistage Dissolution Model

  • Development and Evaluation of Taste-Masked Pediatric Minitablet Formulations with Bitter Model Drugs

  • Best Oral Presentation: Palatability and Acceptability of Multiparticulate Formulations: Adults vs. Children Comparison

7th EuPFI Conference: Antwerp (Belgium) 16th-17th September, 2015

  • Thin Substrates Manufactured by the Means of 3D-Printing-Tailor-Made Drug Delivery Systems for Paediatric Use

  • Preliminary Development of a Tool Assessing the Acceptability of Medicines for Paediatric Use

  • Can Solubilizing Excipients be Used with the Rat BATA Model to Assess the Taste of Poorly Water-Soluble Drugs?

6th EuPFI Conference: Athens (Greece) 17th-18th September, 2014

  • Development and Characterization of Dispersible Tablets Employing Novel Characterization Methods

  • Assessing the Taste of Medicines with Rodents: the In Vivo Rat Brief-Access Taste Aversion (BATA) Model

  • Monitoring Food and Fluid Intake as a Basis for Establishing Biorelevant Dissolution Methods for Children in the Age of 1 - 6 Years

5th EuPFI Conference: Barcelona (Spain) 18th-19th September, 2013

  • Immediate-Release Carbamazepine Formulations for Individual Dosing by the Solid Dosage Pen

  • Development of Buccal Films as Novel Dosage Form for Paediatric Use

  • End-User Perceptions of Solid Oral Dosage Forms in the UK and Canada Part 1: School Children and Adolescents


International Pharmaceutical Federation

PCCA was the exclusive sponsor of the compounding session: The Role of Compounding in Closing Therapeutic Gaps. This 6-hour session included expert speakers from the USA, Portugal, Germany and Spain, who brought together the various compounding specialties, considerations, guidelines and standards.

73rd FIP World Congress: Dublin (Ireland) 31st August – 5th September, 2013


International Pharmaceutical Students’ Federation

PCCA has established a partnership with the IPSF as the official sponsor of the compounding events at the World Congress and Regional Symposia. The IPSF acknowledges the importance and necessity of compounding skills within the pharmacy profession and has created this grant, with the support of PCCA, to allow students around the world the chance to organize their own compounding events.


PCCA was the proud sponsor of the following compounding events:

  • 6th IPSF African Pharmaceutical Symposium (AfPS): Ghana
  • 63rd IPSF World Congress: Taiwan
  • 16th Asia Pacific Pharmaceutical Symposium (APPS): Thailand

PCCA was also the proud sponsor of the IPSF Development Fund Compounding Event (CE) Grants, which were attributed to:

  • Association Tunisienne des Etudiants en Pharmacie (ATEP)
  • Malaysian Pharmacy Students' Association (MyPSA)
  • Zimbabwe Pharmaceutical Students Association (ZPSA)
  • Makerere University Pharmacy Students Association (MUPSA)

PCCA was acknowledged in the IPSF Press Release


PCCA was the proud sponsor of the following compounding events:

  • 5th IPSF African Pharmaceutical Symposium (AfPS): Kenya
  • 62nd IPSF World Congress: Zimbabwe

PCCA was acknowledged in the IPSF Press Release

PCCA was acknowledged in the IPSF Newsletter 107


American Pharmacists Association

2018 APhA Annual Meeting & Exposition: Nashville (USA) 16th-19th March, 2018

  • Stability of Compounded Ursodiol Suspensions in PCCA Base, SuspendIt™


British Small Animal Veterinary Association

BSAVA Congress 2018: Birmingham (UK) 5th-8th April, 2018

  • The use of Lipoderm as a transdermal base in veterinary compounding: A systematic literature review


European Paediatric Formulation Initiative

9th EuPFI Conference: Warsaw (Poland) 20th-21st September, 2017

  • Case Report of a Skin Viral Infection Treated with a Topical Extemporaneous Preparation

  • Physical and Chemical Stability of Phenobarbital 1mg/mL and 50 mg/mL Oral Suspensions (SuspendIt™)



74th FIP World Congress: Dublin (Ireland) 31st August – 5th September, 2013

  • Compounding for Complex Patients: Pediatrics